about the author

Brittany Meiling

editors@endpointsnews.com
Brittany Meiling on LinkedIn

author articles

Valeant nose­dives on CRL for plaque pso­ri­a­sis, rais­ing con­cerns over tout­ed $1B pipeline

7 years ago
R&D
Pharma

Spin­raza ri­val? With DMD flops in the rearview mir­ror, PTC Ther­a­peu­tics posts strong SMA da­ta

7 years ago
R&D

Night­star's drug for rare vi­sion loss ad­mit­ted to FDA's gene ther­a­py speed­way

7 years ago
Pharma
Cell/Gene Tx

Buy­out buzz bumps Madri­gal stock fur­ther north, stok­ing the in­dus­try's NASH ob­ses­sion

7 years ago
Deals

SF ven­ture fund Al­ta Part­ners miss­es orig­i­nal mark, rais­ing $130M for ninth fund

7 years ago
Financing

Step­ping in­to the pric­ing de­bate, FDA chief Scott Got­tlieb pro­pos­es new re­im­burse­ment idea for an­tibi­otics

7 years ago
Pharma

Galmed's stock rock­ets up as ex­ecs tout a mixed set of NASH da­ta

7 years ago
R&D

Af­ter cash fun­nel­ing scan­dal, biotech bil­lion­aire Soon-Sh­iong charges on with Nant IPO

7 years ago
People
Financing

Al­ny­lam's up­dat­ed lumasir­an da­ta points to PhI­II short track; Genen­tech snatch­es fourth ap­proval for Rit­ux­an

7 years ago
News Briefing

Af­ter snatch­ing up Shire's can­cer unit, French phar­ma gi­ant Servi­er to ex­pand US pres­ence with Kendall Square ...

7 years ago
R&D

Ex-con Sam Wak­sal's start­up prices IPO, join­ing pa­rade of biotechs with Nas­daq news

7 years ago
Financing

Re­lo­cat­ing its US HQ to Boston, French phar­ma Ipsen to add 250 jobs

7 years ago
R&D
Pharma

On an ex­ec­u­tive hir­ing spree, Sarep­ta snags Bio­gen's Gilmore O'Neill as new CMO

7 years ago
People

No­to­ri­ous ac­tivist in­vestor Carl Ic­ahn buys small stake in Al­ler­gan

7 years ago
People

Swiss at­tor­ney gen­er­al is­n't pros­e­cut­ing No­var­tis for bribery; Madri­gal to raise $200M in stock sale

7 years ago
News Briefing

Rich Hey­man's Metacrine tacks on an­oth­er $65M to tack­le a su­pe­ri­or NASH drug

7 years ago
Financing
Startups

Genen­tech dives deep­er in­to the mi­cro­bio­me, ink­ing $534M deal with Mi­cro­bi­ot­i­ca to de­vel­op IBD meds

7 years ago
Pharma

FDA vet — and Wood­cock neme­sis — John Jenk­ins is step­ping over to a new role as a board mem­ber at Cor­bus Phar­ma

7 years ago
People

Hours af­ter fil­ing $150M IPO, Tri­ci­da shares pos­i­tive PhI­II tri­al re­sults on CKD drug

7 years ago
Financing

With $1.2B NASH deal be­hind them, Nim­bus rais­es $65M for I/O, oth­er R&D

7 years ago
Financing

Fol­low­ing FDA win, Por­to­la los­es CEO William Lis

7 years ago
People

Sarep­ta snags its part­ner's CSO, Louise Rodi­no-Kla­pac, to lead new gene ther­a­py unit

7 years ago
People

With com­pe­ti­tion on its heels, Blue­print takes three can­cer drugs to Chi­na

7 years ago
China
Pharma

FDA stalls yet an­oth­er Her­ceptin copy­cat, is­su­ing re­sponse let­ter to Am­gen/Al­ler­gan

7 years ago
Pharma
First page Previous page 2345678 Next page Last page
A service from the Financial Times